Byondis B.v.
Clinical trials sponsored by Byondis B.v., explained in plain language.
-
New drug candidate takes on tough lymphoma in first human tests
Disease control OngoingThis study is the first time the drug BYON4228 is being tested in humans. It is for people with a type of blood cancer called B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The study will test the drug alone and combined with ano…
Phase: PHASE1 • Sponsor: Byondis B.V. • Aim: Disease control
Last updated May 06, 2026 08:57 UTC
-
New antibody drug tested for hard-to-treat cancers
Disease control OngoingThis early-phase trial tests a new drug called BYON4228, alone or with another drug (pembrolizumab), in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. Only 7 participants …
Phase: PHASE1 • Sponsor: Byondis B.V. • Aim: Disease control
Last updated Apr 29, 2026 15:14 UTC